PARIS, May 22, 2013 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) reports positive results from two trials evaluating new, innovative drug-eluting stent (DES) technologies, which are emerging treatment options for coronary heart disease. Data from the first human use NG PROMUS Clinical Trial evaluating the safety and effectiveness of the Promus PREMIER™ Everolimus-Eluting Platinum Chromium Coronary Stent System, and two-year follow-up data from the EVOLVE Trial comparing the safety and effectiveness of the SYNERGY Everolimus-Eluting Bioabsorbable Polymer-Coated Platinum Chromium Coronary Stent System to the PROMUS Element™ Stent System were presented today at the annual EuroPCR Scientific Program in Paris.
The NG PROMUS Clinical Trial evaluated the clinical and angiographic outcomes for the Promus PREMIER Stent System at 30 days. John Ormiston, M.D., of Mercy Angiography, Auckland City, New Zealand is the primary investigator for the trial and presented data at the conference.
"The Promus PREMIER Stent demonstrated excellent safety and effectiveness with zero percent target lesion revascularization and stent thrombosis," said Dr. Ormiston. "In addition, the rate of technical success, the primary endpoint of the trial, was very high at 99.2 percent. The Promus PREMIER Stent System truly is a major step forward in stent technology."
The Promus PREMIER Stent System features the only customized stent architecture of its kind providing strength without compromising flexibility. An enhanced low-profile delivery system with a shorter, more visible tip, dual-layer balloon and Bi-Segment™ inner lumen catheter is designed to facilitate precise stent delivery across challenging lesions.Two-year follow-up data from the EVOLVE Trial were also presented today at EuroPCR by Professor Ian Meredith, director of MonashHeart, at Monash Medical Centre in Melbourne, Australia. The primary clinical and angiographic endpoints of this non-inferiority study, which compares the SYNERGY Stent to the PROMUS Element Stent, have already been published. "The clinical results of the SYNERGY Stent in EVOLVE continue to impress with respect to safety and efficacy. At two years, we see no increase in the 1.1 percent target lesion revascularization (TLR) and zero percent stent thrombosis rates that we observed in the full-dose SYNERGY Stent at one year," said Professor Meredith. "Interestingly, the difference in TLR between the PROMUS Element Stent at 6.1 percent and the SYNERGY Stent at 1.1 percent is approaching statistical significance (p=0.07). This is encouraging, as it supports our hypothesis that the bioabsorbable polymer coating could provide a long term benefit over durable polymer coated DES."
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts